Cleveland Clinic Heart Failure Summit Expanding the Frontiers of Contemporary Team Management 2026

* WARNING: This is the full version, not the incomplete one that many other websites are selling cheaply.
12-Jun-2026 to 13-Jun-2026
This comprehensive heart failure and cardiomyopathy program brings together leading experts to explore the latest breakthroughs shaping cardiovascular care. Designed for clinicians across the spectrum of practice, the course delivers cutting-edge insights into HFrEF, genetic and inflammatory cardiomyopathies, metabolic drivers of heart failure, and the rapidly evolving landscape of precision medicine.
Participants will gain practical, evidence-based strategies for optimizing guideline-directed therapy, interpreting emerging clinical trials, and managing complex conditions such as cardiogenic shock, cardiac amyloidosis, and advanced heart failure requiring mechanical circulatory support or transplant evaluation.
With dedicated sessions on future innovations, multidisciplinary intersections, and real-world clinical challenges, this program equips learners with the knowledge and confidence to deliver timely, personalized, and high-quality care to patients with heart failure and cardiomyopathies.
Learning Objectives
Apply precision medicine principles to the evaluation and management of patients with heart failure across the EF spectrum, incorporating genetic, imaging, metabolic, and phenotypic data into individualized care plans.

Integrate contemporary evidence since the 2022 guidelines in GDMT, devices, advanced therapies, and obesity/metabolic treatments into day-to-day clinical decision-making for HFrEF and HFpEF.

Optimize systems of care for complex HF patients by implementing CKM models, population-health strategies, remote monitoring, and equitable access pathways to advanced heart failure therapies.

Select and manage advanced and critical care therapies with greater precision, including temporary and durable mechanical circulatory support, ECMO configurations, and evolving antithrombotic and allocation strategies for LVAD and heart transplantation.

Leverage emerging technologies and innovations such as AI, gene and regenerative therapies, and novel diagnostics to enhance early detection, risk stratification, and personalized treatment of cardiomyopathies and cardiac amyloidosis.

Target Audience
The course is directed toward physicians, physician assistants, nurse practitioners, nurses, and all healthcare providers with an interest in treating and managing patients with heart failure.

+ Topics:

01 GDMT in 2026 Beyond the Guidelines and into Practice
02 Towards Precision Medicine with Cardiac MRI for DCM
03 Genetic Testing What Every HF Clinician Needs to Know
04 Cardiac Sarcoidosis Across the EF Spectrum
05 Cardio-Oncology in the Advanced HF Clinic
06 Session 1 HFrEF, Genetic and Inflammatory Cardiomyopathy Q&A
07 CKM (cardio-kidney-metabolic) Care Models and Practical Implementation
08 Diet and Exercise as Therapeutic Interventions for HFpEF
09 Sex Differences in HFpEF Development and Management
10 Ambulatory PA Monitoring Who, When, How 11 When GDMT Isn’t Enough_ Recognizing Advanced HFrEF Before Its Too Late
12 Session 2 HF and Metabolic Health Q&A
13 HFrEF in the Device Era_ Rise of the Machines
14 The Promise of AI in HF From Risk Prediction to Workflow Integration
15 Gene Therapies The Future of HF Personalized Therapy
16 Implications of a CD36 Genetic Variant as a Cause of Cardiomyopathy
17 Metabolic Health as a Therapeutic Target for HFrEF
18 Session 3 Future Horizons in HF and the Cardiomyopathies Q&A
19 Ventricular Assist Devices 101
20 Heart Transplantation 101
21 Challenging Cases in GDMT Management
22 Diuresis Pathways Across the Spectrum of Care
23 Breakout Session 2 – Top Five Trials of 2025-26 Q&A
24 DIGIT-HF
25 VICTOR
26 SUMMIT and substudies
27 FINEARTS-HF and substudies, RE-DEFINE-HF
28 Neuregulin and Other Regenerative Pathways in HFrEF
30 Equitable Heart Failure Care in a CKM World
31 HF Population Health From Individual Patients to Networks of Care
32 Reframing HF_ Treating and Preventing the Syndrome, Its Causes, and Comorbid Conditions
33 Session 1 Heart Failure at Scale Q&A
34 Cardiogenic Shock in 2026 From Guidelines to Bedside
35 Precision Temporary MCS Devices When, How, and For Whom
36 ECMO Cannulation Strategy_ VA, VAV, LAVA and more
37 Personalizing Care for LVAD Recipients
38 Heart Allocation by Continuous Distribution Are We Nearly There Yet
39 Session 2 Shock and Advanced Therapies Q&A
40 Structural Which Patients with AS and HFrEF Benefit Most from TAVR
41 EP Which Patients with AF Most Benefit from Ablation
42 Surgery Which Patients with HF can Undergo CABG and Valve Surgery
43 AI in Action Practical Tools for the Heart Failure Clinician
44 New Insights Through Imaging and Tracers
45 Evolutions in TTR Therapies
46 Gene editing and TTR removal
47 AL Amyloid Conundrums (Case Based)
48 Educating Patients on an Amyloid Diagnosis
49 Amyloidosis and the Musculoskeletal System
50 Cardiac Amyloid Session Q&A
Friday Session 1 – Updates in HF Epidemiology and Population Health
Friday Session 2 HFrEF and EP Innovations
Friday Session 3 – HFpEF and Pulmonary Hypertension
Friday Session 4A- Meet the Clinical Trialists Concurrent Session
Saturday Session 1- Cardiomyopathies amyloid, HCM, Sarcoid and HFrEF
Saturday Session 2- MCS and TX
Saturday Session 3- Cardiogenic shock and critical care